Precigen, Inc.
NASDAQ:PGENBiotechnology
-$0.10 today
- Market cap
- $1.53B
- Beta
- 1.06
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.65
Volume 4.27M
Average 4.72M
PGEN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Precigen, Inc.NASDAQ: PGEN
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $1.1M rose 74.8% year over year, ahead of the +59.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at -33.3% a year.
Context
- Depreciation & amortization amounted to 33.0% of revenue in FY2025, down 82.3 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +74.8% holds above the trailing-twelve-month pace of +59.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.2M USD
- Year-over-year change
- -29.3%
- 4-year CAGR
- -30.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.2M | -29.3% |
| FY2024 | 2024-12-31 | 4.53M | -32.1% |
| FY2023 | 2023-12-31 | 6.67M | -38.1% |
| FY2022 | 2022-12-31 | 10.77M | -21.8% |
| FY2021 | 2021-12-31 | 13.76M | — |
Depreciation & Amortization vs competitors
How PGEN compares with its peers on the latest reported figures
- PGEN's LTM Jun 2026 depreciation & amortization of $4.14M is the 6th largest of the 8 companies compared; the peer median is $9.99M.
- Its year-over-year change of +59.6% is the highest of 8, against a peer median of -2.7%.
- Depreciation & amortization amounts to 4.8% of revenue for PGEN, versus a peer median of 16.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $18.5M | -0.9% | -6.9% | 73.5% | |
| LTM Mar 2026 | $15.52M | -3.0% | +6.5% | 17.7% | |
| LTM Mar 2026 | $10.18M | +0.4% | +20.7% | — | |
| LTM Mar 2026 | $9.99M | -2.7% | +10.7% | 15.1% | |
| LTM Mar 2026 | $4.17M | -34.0% | -5.9% | 10.8% | |
| LTM Jun 2026 | $4.14M | +59.6% | -33.3% | 4.8% | |
| LTM Mar 2026 | $3.62M | +20.6% | -8.0% | 24.9% | |
| LTM Mar 2026 | $2.69M | -30.3% | -32.6% | 6.0% | |
| Peer median (excluding PGEN) | $9.99M | -2.7% | -5.9% | 16.4% | |
Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (92.17M) | 28.32M | (95.9M) | (126.24M) | (250.64M) |
| Depreciation & Amortization | 13.76M | 10.77M | 6.67M | 4.53M | 3.2M |
| Deferred Income Tax | (167K) | (150K) | (479K) | (1.8M) | 0 |
| Stock-Based Compensation | 13.9M | 10.21M | 9.89M | 9.47M | 10.87M |
| Change in Working Capital | (804K) | (35.7M) | 17.07M | 4.52M | 6.62M |
| Accounts Receivables | (6.56M) | (13.51M) | 12.23M | 414K | (3.2M) |
| Inventory | (1.9M) | 2.34M | 0 | 0 | (9.21M) |
| Accounts Payables | 420K | 379K | (2.42M) | 1.55M | 8.77M |
| Other Working Capital | 7.24M | (24.91M) | 7.26M | 2.56M | 10.26M |
| Other Non-Cash Items | 9.7M | (78.48M) | (4.17M) | 41.34M | 142.12M |
| Operating Cash Flow | (55.77M) | (65.05M) | (66.93M) | (68.17M) | (87.83M) |
| Capital Expenditures | (7.25M) | (4.92M) | (1.54M) | (8.58M) | (2M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (174.22M) | 0 | (185.03M) | (187.21M) | (208.01M) |
| Sales of Investments | 100.17M | 68.44M | 183.38M | 175.02M | 208.47M |
| Other Investing Activities | 6.76M | 162.9M | 98K | 60K | 0 |
| Investing Cash Flow | (74.54M) | 226.42M | (3.09M) | (20.71M) | (1.54M) |
| Debt Repayment | (466K) | (155.29M) | (43.22M) | 0 | 92.82M |
| Common Stock Issued | 121.05M | 0 | 72.81M | 31.24M | 310K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 608K | 1K | 0 | 346K | (3.08M) |
| Financing Cash Flow | 121.19M | (155.29M) | 29.59M | 110.58M | 90.05M |
| Effect of Forex Changes | 217K | (827K) | (320K) | (27K) | 35K |
| Net Change in Cash | (8.91M) | 5.25M | (40.75M) | 21.67M | 717K |
| Free Cash Flow | (63.02M) | (69.97M) | (68.47M) | (76.76M) | (89.83M) |
Precigen, Inc.
NASDAQ:PGEN
Intrinsic Alpha fair value
Locked
Current Price
$4.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.